An orphan-designated medicine Translarna (ataluren), Recommended by The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) with granting a conditional marketing authorisation for the treatment of Duchenne muscular dystrophy caused by nonsense mutations. Translarna is to be used in patients aged five years and older who are able to walk. a href="http:http://ift.tt/1nsXwGz" target="_blank" class="vcontentshlink"Duchenne ...
via Medindia Health News
More READ 
Lake forest health and fitness http://ift.tt/1pdgeUG
No comments:
Post a Comment